Justin Loke
Name
Justin Loke
Job title
Honorary Consultant Haematologist
Email Address
the-christie.haemsecretaries@nhs.net
Phone number
0161 956 1531
Qualifications
MA BM BCh PhD MRCP FRCPath
Specialities
Haematology
Started at The Christie (Year)
2025
Responsibilities
Institute Fellow, Cancer Research UK Manchester Institute, Head Myeloid Cancer Biology
Professional biography
Dr Justin Loke trained at the University of Cambridge and Oxford Medical School and then completed postgraduate haematology training in Birmingham. His specialist interest is in Acute Myeloid Leukaemia (AML) and he completed his PhD at the University of Birmingham under the supervision of Professor Constanze Bonifer in the epigenetic deregulation of AML, for which he was awarded a number of prizes from the Royal Society of Medicine and the Royal College of Pathologists.
Dr Loke subsequently completed a post-CCT fellowship with CRUK Clinical Trials Unit, Birmingham, and was a Consultant Haematologist at the Queen Elizabeth Hospital, Birmingham where he was involved in the development of supportive care studies in AML (PACE) and in the running of IMPACT transplant studies.
He obtained funding as an AACR-CRUK Transatlantic Fellow based in the Dana Farber Cancer Institute, Boston, USA with Professor Ben Ebert.
In August 2025, Dr Loke was appointed to the Amit Patel Leukaemia Research Fellowship. This prestigious research fellowship is awarded in memory of Professor Amit Patel, Consultant Haematologist at The Christie, who sadly passed away in 2021.
Dr Loke takes up his new position as Institute Fellow in the Cancer Research UK Manchester Institute in November 2025, where he will establish his research group, Myeloid Cancer Biology.
Publications
Other publications
- RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
- Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
- Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
- An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesis